Answers are grounded in this paper and cite their sources.
Experimental study reveals distinct activation mechanisms for shape change and exocytosis in human eosinophils, indicating motility does not require classical calcium signaling.
Essentially pure preparations of normal density eosinophils ob- tained from patients with hypereosinophilic syndrome (HES) were stimulated with complement factor 5a (C5a), platelet-acti- vating factor (PAF), FMLP and neutrophil-activating peptide (NAP-1/IL-8). Three responses were studied, the transient rise in cytosolic free calcium concentration (ICa2+j (derived from indo-1 fluorescence), shape changes (measured by laser turbi- dimetry), and exocytosis of eosinophil peroxidase (EPO) (as- sessed by H202/luminol-dependent chemiluminescence). Re- sponses were obtained with all four agonists, but C5a and PAF were by far more potent than FMLP and NAP-1/IL-8, which induced only minor effects. Pretreatment of the cells with per- tussis toxin attenuated ICa2+h changes, EPO release and, to a lesser extent, shape changes, indicating that GTP-binding pro- teins of Gi-type are involved in receptor-dependent signal trans- duction processes leading to these responses. A clear dissociation was observed in the control of the shape change response and EPO exocytosis. The shape change was not affected by Ca2' depletion or treatment with the protein kinase inhibitor staurosporine, but exocytosis was prevented by Ca2' depletion and markedly enhanced by staurosporine. The activation of the contractile system, leading to shape changes and motility, thus appears to be independent of the classical signal transduction pathway involving phospholipase C, a [Ca2j11 rise and protein kinase C activation. Exocytosis is, as expected, CIO+ dependent and appears to be under a negative control involving protein phosphorylations. (J. Clin. Invest. 1991 . 87:2012-2017.) Key words: signal transduction * hypereosinophilic syndrome * tur- bidimetry * calcium depletion -staurosporine OR). Recombinant NAP-l/IL-8 was obtained from the Sandoz Re- search Institute, Vienna, Austria (19), and recombinant human GM- CSF (batch No. 860107.00) from Sandoz Ltd., Basel, Switzerland. C5a was prepared as described by Hugh et al. (20).
No takes yet. Share an insight, caveat, or question.
Kernen et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: